Human Journals

Case Report

January 2020 Vol.:17, Issue:2

© All rights are reserved by HARIS MOHAMED K M et al.

Escitalopram Induced QTc Prolongation: A Case Report



HARIS MOHAMED K M*1, AMALA T A², SREEJA $P \ A^2$

¹Clinical Pharmacist, Aster Medcity, Kochi, Kerala 682027.

²Department of Pharmacy Practice, Grace College of Pharmacy, Palakkad, Kerala 678004.

Submission:22 December 2019Accepted:28 December 2019Published:30 January 2020

Keywords: Escitalopram, SSRIs, QTc prolongation

ABSTRACT

Adverse drug reaction (ADR) can be defined as any noxious change which is suspected to be due to a drug, occurs at doses normally used in man, requires treatment or decrease in dose or indicates caution in the future use of the same drug. ESCITALOPRAM is a drug which comes under the category of selective serotonin reuptake inhibitors (SSRIs) (antidepressants). It is the S-enantiomer of the racemic derivative of citalopram, which selectively inhibits the reuptake of serotonin with little to no effect on norepinephrine or dopamine reuptake. Almost all the antidepressants and antipsychotics have been linked to QT prolongation.





www.ijppr.humanjournals.com

INTRODUCTION

Adverse drug reaction (ADR) can be defined as any noxious change which is suspected to be due to a drug, occurs at doses normally used in man, requires treatment or decrease in dose or indicates caution in the future use of the same drug.

A QT interval or QTC is an electrocardiographic measure of ventricular repolarization and depolarization. (1,1)

The normal value of QT interval is less than 450ms in men and 460ms in women. (1,2)

Antiarrhythmics, antibiotics, antipsychotics, antidepressants are some of the medications /drugs can lead to prolonged QT interval. (1,3)

There are some risk factors for QT prolongation are female sex, age greater than 65year, electrolyte disturbances (hypokalemia, hypomagnesemia) concomitant QT-prolonging medications.^(1,4)

The United States Food and Drug Administration (FDA) ICH E14 guidance for clinical evaluation of QT/QTc interval prolongation and pro-arrhythmic potential for non-arrhythmic drugs established the threshold is in Table 1:

Table No. 1: US FDA E14 guidance for drug-induced QTc prolongation

Change from baseline QTc placebo correct	Interpretation
<10 ms	Low concern
10-20ms, QTc outliers +- clinical AES	Increasing concern
>20ms, +QTc outliers +- clinical AEs	Definite concern

- QTc outliers: individual-level QTc > 500ms or change in QTc > 60ms
- Clinical AEs(Adverse Events): TdP, sudden death, ventricular tachycardia, ventricular fibrillation or flutter, syncope, seizure
- AE: TdP, torsades de pointes; US FDA; US Food and Drug Administration (1,5)

The study conducted in Unites States from 2011 - 2014 reported that the prevalence of QTc prolongation in adults on antidepressant therapy is 1% above in 60years or more of age.

ESCITALOPRAM is a drug which comes under the category of selective serotonin reuptake inhibitors(SSRIs) (antidepressants). It is the S-enantiomer of the racemic derivative of citalopram, which selectively inhibits the reuptake of serotonin with little to no effect on norepinephrine or dopamine reuptake. Escitalopram is metabolized by hepatic metabolism via CYP2C19 and CYP3A4 to S-desmethyl citalopram (S-DCT). S-DCT is metabolized to S-didesmethyl citalopram (S-DDCT) via CYP2D6.

There are some monitoring parameters to check if a patient is on escitalopram including QTc changes, electrolyte, liver and renal function tests. Prolonged QT interval on ECG is reported in several studies as an adverse drug reaction. ⁽⁶⁾

CASE REPORT

A 68 year old female patient was admitted for the diagnosis of osteoporotic fracture with cord compression. She was a known case of hypertenstion and on medication T.Amlong 10mg for the past 3 years. She was admitted under the department of neurosurgery in a quaternary care hospital. She was treated with calcium and phosphorus with vitamin D chewable tablets once daily, Teriparatide 20mg once daily, Inj.paracetamol 1gm thrice daily after the fixation surgery. The patient showed signs of depression and was advised to take Tab. Escitalopram 10mg from the second day of admission. Electrolyte disturbances were seen, a mainly hypokalemic pattern was shown in the ECG. The ECG report shows a QTc interval of 454ms on the first day. After the escitalopram treatment was initiated, the patient showed a QTc interval of 505ms. The potassium level was found to be 2.8mg/dl on the first day(hypokalemia), along with QTc prolongation, which was treated with syrup potassium chloride 15ml thrice daily and serum potassium level increased to 3.4mg/dl.




FIGURE NO. 1: ECG report before escitalopram treatment




FIGURE NO. 2: ECG report after escitalopram treatment.

DISCUSSION

Depression is currently one of the fastest rising diagnosis made by the physicians during the past 5 years and hence there has been an increasing trend in the utilization of escitalopram. Three cases of QTc prolongation with escitalopram was reported. (7,8,9) The drug-induced QT

prolongation is thought to be caused by the inhibition of delayed potassium rectifier current IKr (rapid) by specific drugs. IKr is an outward current controlled by the potassium channel that is responsible in part for the repolarization of ventricular myocytes. When a drug interferes with this current, it thereby disrupts repolarization and hence the QT interval is prolonged. (7,10)

PSYCHIATRIC DRUGS WITH A HIGHER RISK OF QTc PROLONGATION		
AT THERAPEUTIC LEVELS		
DRUG CLASS	DRUG NAME	
	Thioridazine,	
Typical antipsychotics	Haloperidol	
	Chlorpromazine	
	Ziprasidone	
Atypical antipsychotics	Iloperidone	
	Quetiapine	
SSRIs	Citalopram	
	Escitalopram	
	Amitriptyline	
	Imipramine	
TCAs and TeCAs	Maprotiline	
	Nortriptyline	
	Clomipramine	
SNRIs	Venlafaxine	
	Duloxetine	
QTc corrected QT: SNRI: sel	lective norepinephrine reuptake inhibitor, SSRI; selective	
serotonin reuptake inhibitor,	TCA; tetracyclic antidepressants	
Source: Reference;11-16		

CONCLUSION

Almost all the antidepressants and antipsychotics have been linked to QT prolongation. The common medications that are considered to have high risk are Selective serotonin reuptake inhibitors mainly escitalopram. New studies on this topic are expected to emerge owing to the FDA's requirement to investigate the cardiac profiles of the medication.

ABBREVIATIONS

SNRI-Selective norepinephrine reuptake inhibitor, SSRI- selective serotonin reuptake inhibitor, ECG-Electrocardiogram

CONFLICT OF INTEREST

Declared none.

REFERENCES

- 1. Paul Singh, J.martin Maldonado. Drug-induced QT prolongation as a result of an escitalopram overdose in a patient with previously undiagnosed congenital long QT syndrome. *Hindawi*. 917846,2014.
- 2. P.J.Schwartz, M stramba-badiale, L.Crotti et al. Prevalence of congenital long QT syndrome. *Circulation*, vol.120 No. 18, pp.1761-1767,2009.
- 3. H.C Bazett, The time relations of the blood pressure changes after excision of the adrenal glands, with some observations on blood volume changes. *The journal of physiology*, vol.53,no.5,pp.320-33,1920.
- 4. Z.A.Bhuiyan, S.al-shahrani J.Al-Aama, A.Wilde, and S. Momenah. Congenital long QT syndrome; an update and present perspective in Saudi Arabia. *Frontiers in pediatrics*, vol.1.39,2013.
- 5. S.Kanjanauthi, T.Kanleun, and P.Chareonnthaitawee. Citalopram induced torsades de pointes, a rare lifethreatening side effect. *International journal of cardiology*. Vol.131, no.1,pp.e33-e34,2008.
- 6. Lexicomp.online
- 7. Aimee Dietle.QTc prolongation with antidepressants and antipsychotics. *US Pharm.* 40(11);HS34-HS40,2015.
- 8. Woosley RL, Romeo KA. QT drugs list. www.crediblemeds.org.
- 9. Hasnain M, Miceli JJ, Anziano R et al. A randomized evaluation of the effects of six antipsychotic agents on QTc in the absence and presence of metabolic inhibition. *J Clin Psychopharmacology*. 24:62-69,2004
- 10. Hasnian M, Viweg WV, Howland RH et al. Quetiapine and the need for a thorough QT/QTc study. *J Clin Psychopharmaco*1;34-36,2014.
- 11. Potkin SG, Preskon S, Hochmeld M, Meng X. A thorough QTc study of 3 doses of iloperidone including metabolic inhibition via CYP2D6 and comparison to quetiapine and ziprasidone. *J Clin Psychopharamcol.* 33;3-10,2014.
- 12. Camm AJ, Karayal ON, Meltzer H. ziprasidone and the corrected QT interval;a comprehensive summary of clinical data.CNS drugs.26;351-355,2012.
- 13. Chapel S, Hutmcher MM et al.comparsison of QTc data analysis methods recommended by the ICH E14 guidance and exposure response analysis; case study of a thorough QT study of asenapine.62;191-198,2011.
- 14. Van Norrd C, Straus SM, Strkenboorn MC et al. Psychotropic drugs associated with corrected QT interval prolongation. *J Clin Psychopharmacol*. 29;9-15,2009.
- 15. Funk KA, Bostwick JR. A comparison of the risk of QT prolongation among SSRIs. *Ann pharmacother*. 47;1330-1341,2001
- 16. Beach Sr, Kotstis WJ, Celani CM et al. Meta Analysis of Selective serotonin reuptake inhibitor associated QT c prolongation. *J Clin Psychiatry*. 75;e441-e449,2014.